TABLE 3.

Subgroup Analysis^a

Subgroup analysis	No. of cohorts	RR	95% CI	P value for difference between the subgroupsb
Mortality
Duration of therapy from stroke onset
≤6 h	4	1.07	0.75–1.50	.39
≥6 h	2	0.76	0.38–1.51
Study location
US	4	0.86	0.65–1.15	.08
Non-US	2	1.43	0.87–2.36
Study setting
Multicenter	5	0.98	0.76–1.25	NA
Monocenterc	1	NA	NA
mRS score ≤1
Duration of therapy from stroke onset
≤6 h	3	1.05	0.80–1.38	.56
>6 h	2	0.73	0.23–2.36
Study location
US	3	1.06	0.82–1.38	.85
Non-US	2	1.14	0.59–2.19
Study setting
Multicenter	5	1.02	0.84–1.23	NA
Monocenterc	1	NA	NA
mRS score ≤2
Duration of therapy from stroke onset
≤6 h	3	1.06	0.83–1.35	.38
>6 h	2	0.71	0.30–1.69
Study location
US	3	1.04	0.86–1.26	70
Non-US	2	1.19	0.61–2.32
Study setting
Multicenter	5	1.02	0.84–1.24	NA
Monocenterc	1	NA	NA
mRS score ≤3
Duration of therapy from stroke onset
≤6 h	3	1.05	0.94–1.16	26
>6 h	2	0.78	0.48–1.28
Study location
US	3	1.03	0.90–1.18	.88
Non-US	2	1.03	0.89–1.20
Study setting
Multicenter	5	1.03	0.93–1.14	NA
Monocenterc	1	NA	NA
sICH
Duration of therapy from stroke onset
≤6 h	4	0.96	0.62–1.58	.63
>6 h	2	1.50	0.27–8.42
Study location
US	3	1.06	0.59–1.92	77
Non-US	3	0.89	0.42–1.89
Study setting
Multicenter	5	1.02	0.64–1.63	.55
Monocenterc	1	0.42	0.02–7.71

^amRS = modified Rankin scale; NA = not applicable/available; RCT = randomized controlled trial; RR = risk ratio; sICH = symptomatic intracranial hemorrhage.

^bP<.10 implies that difference between the 2 subgroups is significant, and it may explain the heterogeneity observed in the overall analysis.

^cSen et al²²; in this RCT, no patient died and authors did not report the mRS score as an outcome.